Soditic Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Soditic Asset Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$10.6M	Hold	31,727	–	–	10.79%	4
2024 Q2	$8.66M	Hold	31,727	–	–	10.04%	4
2024 Q1	$11M	Sell	31,727 -5,392	-15%	-$1.77M	13%	4
2023 Q4	$12M	Sell	37,119 -556	-1%	-$174K	8.71%	5
2023 Q3	$13.5M	Hold	37,675	–	–	10.4%	4
2023 Q2	$14.3M	Buy	37,675 +15,425	+69%	+$6.28M	10.42%	4
2023 Q1	$10.7M	Buy	22,250 +810	+4%	+$379K	11.8%	3
2022 Q4	$9.02M	Buy	21,440 +1,710	+9%	+$690K	11.16%	4
2022 Q3	$8.23M	Hold	19,730	–	–	10.26%	4
2022 Q2	$9.77M	Buy	19,730 +3,250	+20%	+$1.69M	7.5%	6
2022 Q1	$9.28M	Hold	16,480	–	–	5.49%	9
2021 Q4	$12.5M	Hold	16,480	–	–	6.42%	9
2021 Q3	$12.3M	Hold	16,480	–	–	5.82%	10
2021 Q2	$10.6M	Hold	16,480	–	–	5.36%	10
2021 Q1	$9.41M	Buy	16,480 +7,560	+85%	+$4.48M	4.84%	11
2020 Q4	$5.2M	Buy	+8,920	New	+$5.08M	5.18%	10

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Soditic Asset Management's BIO Position: Q3 2024 in Review

Soditic Asset Management held its Bio-Rad Laboratories Class A (BIO) position steady in Q3 2024 at 31,727 shares worth $10.6M. The position accounts for 10.79% of the portfolio, ranked #4.

Soditic Asset Management first reported a position in BIO in Q4 2020 and has held it in 16 quarters since. The position peaked at $14.3M in Q2 2023. 438 funds tracked by Wall St. Rank hold BIO as of Q3 2024.

Soditic Asset Management held 31,727 shares of Bio-Rad Laboratories Class A worth $10.6M as of Q3 2024.
Soditic Asset Management left its Bio-Rad Laboratories Class A share count unchanged in Q3 2024.
Bio-Rad Laboratories Class A made up 10.79% of Soditic Asset Management's portfolio in Q3 2024, its #4 holding.
Soditic Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and has held it in 16 quarters since.
Soditic Asset Management's Bio-Rad Laboratories Class A position peaked at $14.3M in Q2 2023.
438 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2024.

Based on Soditic Asset Management's 13F filing for Q3 2024, filed 6 Nov 2024.